Replimune Stock Surges After FDA Panel Endorses Skin-Cancer Trial
TL;DR Summary
Replimune’s RP1 melanoma immunotherapy saw its shares jump about 107% after a FDA advisory committee voted 10-3 that the study results were valuable and clinically meaningful, a boost for accelerated approval prospects despite prior BLA denials in 2025; analysts subsequently upgraded the stock.
- This Biotech Stock Soars 107% After Key FDA Panel Vote on Skin Cancer Treatment Barron's
- Opinion | Replimune’s Melanoma Therapy Gets a Thumbs Up WSJ
- Replimune melanoma drug wins support of FDA panel BioPharma Dive
- US FDA advisers back Replimune skin cancer drug trial data Reuters
- REPL Stock Tracks Best Day Ever: This Analyst Sees Higher Approval Odds For Replimune’s Melanoma After ‘Overwhelmingly Positive’ Panel Outcome finance.yahoo.com
Reading Insights
Total Reads
0
Unique Readers
3
Time Saved
18 min
vs 19 min read
Condensed
99%
3,711 → 43 words
Want the full story? Read the original article
Read on Barron's